⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
ImmunityBio’s ANKTIVA ® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
businesswire.com
IBRX
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA ®, NK Cell Therapy Plus Optune Gio ® Device
businesswire.com
IBRX